Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.
(2002) In European Respiratory Journal 20(5). p.1138-1146
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/114693
- author
- Wadbo, Monika LU ; Löfdahl, Claes-Göran LU ; Larsson, K ; Skoogh, B E ; Tornling, G ; Arweström, E ; Bengtsson, T and Ström, K
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cholinergic Antagonists: adverse effects, Carbon Dioxide: blood, Chronic Obstructive: physiopathology, Quality of Life, Vital Capacity, Walking, Chronic Obstructive: drug therapy, Pulmonary Disease, Adrenergic beta-Agonists: adverse effects, Adrenergic beta-Agonists: therapeutic use, Adult, Aged, Bronchodilator Agents: adverse effects, Bronchodilator Agents: therapeutic use, Cholinergic Antagonists: therapeutic use, Comparative Study, Double-Blind Method, Dyspnea: etiology, Ethanolamines: adverse effects, Ethanolamines: therapeutic use, Female, Forced Expiratory Volume, Human, Ipratropium: adverse effects, Ipratropium: therapeutic use, Male, Middle Age, Oxygen: blood, Physical Endurance
- in
- European Respiratory Journal
- volume
- 20
- issue
- 5
- pages
- 1138 - 1146
- publisher
- European Respiratory Society
- external identifiers
-
- wos:000179176500011
- pmid:12449166
- scopus:0036849465
- ISSN
- 1399-3003
- DOI
- 10.1183/09031936.02.00301702
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Respiratory Medicine and Allergology (013230111), Lung medicine (Malmö) (ceased) (LUR000013), Division of Clinical Chemistry and Pharmacology (013250300)
- id
- 1a078872-a900-4929-93b8-fef3cd93d306 (old id 114693)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12449166&dopt=Abstract
- date added to LUP
- 2016-04-01 12:11:05
- date last changed
- 2022-01-26 23:58:41
@article{1a078872-a900-4929-93b8-fef3cd93d306, author = {{Wadbo, Monika and Löfdahl, Claes-Göran and Larsson, K and Skoogh, B E and Tornling, G and Arweström, E and Bengtsson, T and Ström, K}}, issn = {{1399-3003}}, keywords = {{Cholinergic Antagonists: adverse effects; Carbon Dioxide: blood; Chronic Obstructive: physiopathology; Quality of Life; Vital Capacity; Walking; Chronic Obstructive: drug therapy; Pulmonary Disease; Adrenergic beta-Agonists: adverse effects; Adrenergic beta-Agonists: therapeutic use; Adult; Aged; Bronchodilator Agents: adverse effects; Bronchodilator Agents: therapeutic use; Cholinergic Antagonists: therapeutic use; Comparative Study; Double-Blind Method; Dyspnea: etiology; Ethanolamines: adverse effects; Ethanolamines: therapeutic use; Female; Forced Expiratory Volume; Human; Ipratropium: adverse effects; Ipratropium: therapeutic use; Male; Middle Age; Oxygen: blood; Physical Endurance}}, language = {{eng}}, number = {{5}}, pages = {{1138--1146}}, publisher = {{European Respiratory Society}}, series = {{European Respiratory Journal}}, title = {{Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.}}, url = {{http://dx.doi.org/10.1183/09031936.02.00301702}}, doi = {{10.1183/09031936.02.00301702}}, volume = {{20}}, year = {{2002}}, }